This post by IRMA’s Jim Pickett first appeared on the blog of the HIV Prevention Justice Alliance. The VOICE results are extremely important to the field of new prevention technology research. I hope current/future/much-needed discussions about VOICE don’t get drowned out by the HYPE (yes, all caps HYPE) surrounding the “baby cure” story which has dominated coverage out Read More >>

[Click here for the VOICE press release – “Daily HIV Prevention Approaches Didn’t Work for African Women in the VOICE Study” – from the Microbcide Trials Network] IRMA, like the rest of new prevention technology researchers and advocates, is disappointed to learn that daily oral Truvada was not found to be an effective HIV intervention among the African women at Read More >>

via IRMA/AVAC, presented by Jim A. Turpin Please register for this teleconference.  Meeting Description: In the last two years there has been great progress in ARV-based prevention strategies – both in terms of PrEP and microbicides. Specifically, there has been enormous excitement and promise around two drugs – tenofovir and Truvada. And more recently, studies testing Dapivirine Read More >>

via Citizen News Service, by Bobby Ramakant At the recently concluded XIX International AIDS Conference (AIDS 2012), not only the decibels went up on ending AIDS but also sane voices were heard demanding a well-costed and thought-through strategy on how to end AIDS. One of the strategies that will complement a comprehensive HIV prevention, treatment, care and Read More >>

via Morbidity and Mortality Weekly Report In the United States, an estimated 48,100 new human immunodeficiency virus (HIV) infections occurred in 2009 (1). Of these, 27% were in heterosexual men and women who did not inject drugs, and 64% were in men who have sex with men (MSM), including 3% in MSM who inject drugs. In January Read More >>

Check out this interesting mini-bio of Wipas Wimonsate (Toon), the latest in IRMA’s “Meet a Friendly Rectal Microbicide Advocate” series on the IRMA website here.  Toon is one of the six new bios just posted the other day, including individuals from Thailand, Kenya and the US.  Each will be featured on the blog, and you can read all Read More >>

Check out this interesting mini-bio of Amber Rucker, the latest in IRMA’s “Meet a Friendly Rectal Microbicide Advocate” series on the IRMA website here.  Amber is one of six new bios just posted the other day, including individuals from Thailand, Kenya and the US.  Each will be featured on the blog, and you can read all of Read More >>

[Press release from AIDS Foundation of Chicago – home to IRMA] Historic decision makes Truvada the first drug approved to reduce the risk of HIV infection from sexual contact among HIV-negative individuals at elevated risk of infection Today, the U.S. Food and Drug Administration approved the use of Gilead’s  antiretroviral drug Truvada for HIV prevention — known Read More >>

Check out this interesting mini-bio of Pedro Goicochea, the latest in IRMA’s “Meet a Friendly Rectal Microbicide Advocate” series on the IRMA website here.  Pedro is one of six new bios just posted today, including individuals from Kenya,Thailand and the US.  Each will be featured on the blog, and you can read all of them here right Read More >>

via aidsmap.com, by Gus Cairns Within the next three years, up to 33,000 people may take part in 22 different studies worldwide to demonstrate the feasibility, or otherwise, of pre-exposure prophylaxis (PrEP) to prevent HIV, the IAPAC evidence summit, Controlling the HIV epidemic with antiretrovirals, was told on 12 June.Some of these studies are underway but others Read More >>